Clinical Trials Logo

Clinical Trial Summary

Functional and ultrasound-guided resection of glioblastoma: assessing the use of additional imaging during surgery to improve outcomes for patients with glioblastoma brain tumours


Clinical Trial Description

Stage 1 (IDEAL IIB study) of the trial is observational only and all participants will receive all technologies during surgery. Stage 2 will be randomised. Randomisation will be via the web-based service provided by the Oxford Clinical Trials Research Unit (OCTRU), using the method of minimisation. Participants will be randomised 1:1 to either: 1. Standard care surgery (neuronavigation based on preoperative imaging and intraoperative use of 5-ALA)(Control arm) 2. Standard care surgery (neuronavigation based on preoperative imaging and intraoperative use of 5-ALA) AND of DTI neuronavigation and NiUS (Intervention arm) At baseline all participants will undergo a routine preoperative neuronavigation MRI scan. Those participants randomised to the experimental arm, will also have a DTI scan (additional 5 minutes in the MRI). All participants will then undergo the planned resection of their tumour, with the additional technologies if they are in the experimental arm. Following surgery, participants in both arms have the same follow up schedule and undergo standard clinical care for a total of 24 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05399524
Study type Interventional
Source University of Oxford
Contact Amy Taylor
Phone 44 7917 101 649
Email futuregb@nds.ox.ac.uk
Status Recruiting
Phase N/A
Start date November 1, 2020
Completion date November 2025

See also
  Status Clinical Trial Phase
Completed NCT03990285 - [18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin ) Phase 1
Completed NCT05896449 - Predictive Values of Preoperative [68Ga]Ga-PSMA-11 PET/CT in Patients With Suspected Brain Tumours of Glial Origin N/A
Recruiting NCT05086497 - WBSI Guided Personalized Delivery of TTFields N/A
Recruiting NCT06348693 - Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness